Amgen (NASDAQ:AMGN – Get Rating) updated its FY22 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $17.00-18.00 for the period, compared to the Thomson Reuters consensus estimate of $17.61. The company issued revenue guidance of $25.4-26.5 billion, compared to the consensus revenue estimate of $26.09 billion.
A number of brokerages recently weighed in on AMGN. Wells Fargo & Company raised their price target on shares of Amgen from $210.00 to $250.00 and gave the company an equal weight rating in a report on Wednesday, February 9th. Bank of America lowered shares of Amgen from a buy rating to a neutral rating and lowered their price target for the company from $285.00 to $255.00 in a report on Wednesday, January 5th. StockNews.com lowered shares of Amgen from a strong-buy rating to a buy rating in a report on Tuesday, April 5th. Barclays lifted their target price on shares of Amgen from $233.00 to $236.00 and gave the stock an equal weight rating in a report on Tuesday, April 12th. Finally, Morgan Stanley lowered their target price on shares of Amgen from $238.00 to $237.00 and set an equal weight rating for the company in a report on Tuesday, April 12th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Amgen currently has an average rating of Hold and an average target price of $237.50.
Shares of NASDAQ AMGN traded down $4.94 during midday trading on Friday, reaching $233.19. 4,029,302 shares of the stock were exchanged, compared to its average volume of 2,581,127. The business has a 50-day simple moving average of $239.49 and a two-hundred day simple moving average of $225.25. The company has a market capitalization of $124.47 billion, a price-to-earnings ratio of 22.95, a P/E/G ratio of 1.48 and a beta of 0.59. Amgen has a 12 month low of $198.64 and a 12 month high of $258.81. The company has a debt-to-equity ratio of 4.96, a current ratio of 1.59 and a quick ratio of 1.26.
Amgen (NASDAQ:AMGN – Get Rating) last posted its quarterly earnings data on Wednesday, April 27th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.10 by $0.15. Amgen had a net margin of 21.75% and a return on equity of 129.38%. During the same period in the previous year, the company posted $3.70 EPS. Equities research analysts expect that Amgen will post 17.53 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 8th. Investors of record on Tuesday, May 17th will be given a $1.94 dividend. The ex-dividend date is Monday, May 16th. This represents a $7.76 annualized dividend and a yield of 3.33%. Amgen’s dividend payout ratio is currently 76.38%.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Ulland Investment Advisors LLC bought a new stake in Amgen in the 4th quarter valued at $45,000. OLD Mission Capital LLC bought a new stake in Amgen in the 3rd quarter valued at $239,000. Autumn Glory Partners LLC bought a new stake in Amgen in the 4th quarter valued at $300,000. Zullo Investment Group Inc. bought a new stake in Amgen during the 4th quarter worth about $300,000. Finally, Roberts Capital Advisors LLC acquired a new position in shares of Amgen during the 4th quarter worth about $337,000. 74.53% of the stock is currently owned by institutional investors and hedge funds.
About Amgen (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.